Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF) Short Interest Update

Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF) (TSE:CPH) was the recipient of a significant growth in short interest in November. As of November 30th, there was short interest totalling 142,800 shares, a growth of 15.2% from the November 15th total of 124,000 shares. Based on an average daily trading volume, of 31,500 shares, the days-to-cover ratio is presently 4.5 days.

Cipher Pharmaceuticals Stock Up 1.1 %

Shares of Cipher Pharmaceuticals stock traded up $0.11 during trading on Friday, hitting $10.01. 8,577 shares of the stock were exchanged, compared to its average volume of 23,019. The stock’s fifty day moving average is $11.03 and its 200 day moving average is $9.67. Cipher Pharmaceuticals has a 12 month low of $4.14 and a 12 month high of $14.60.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.